TEVA PHARMA INDUSTRIES LTD ADR

NYSE: TEVA (Teva Pharmaceutical Industries)

Last update: 04 Jun, 6:10PM

17.52

0.33 (1.92%)

  • 1D 1.92%
  • 5D -1.41%
  • 1M 2.94%
  • 6M -17.79%
  • YTD -17.75%
  • 1Y 2.70%
  • 5Y 38.28%
Previous Close 17.19
Open 17.19
Volume 11,142,735
Avg. Volume (3M) 12,479,676
Market Cap 20,129,605,632
Price / Earnings (Forward) 6.54
Price / Sales 1.17
Price / Book 3.11
52 Weeks Range
12.47 (-28%) — 22.80 (30%)
Earnings Date 29 Jul 2025 - 5 Aug 2025
Profit Margin -7.74%
Operating Margin (TTM) 18.22%
Diluted EPS (TTM) -1.15
Quarterly Revenue Growth (YOY) 1.90%
Total Debt/Equity (MRQ) 270.20%
Current Ratio (MRQ) 1.03
Operating Cash Flow (TTM) 1.27 B
Levered Free Cash Flow (TTM) 1.66 B
Return on Assets (TTM) 5.27%
Return on Equity (TTM) -19.11%

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - Specialty & Generic (US) Bearish Mixed
Drug Manufacturers - Specialty & Generic (Global) Bearish Mixed
Stock Teva Pharmaceutical Industries Bearish Bullish

AIStockmoo Score

2.1
Analyst Consensus 2.0
Insider Activity NA
Price Volatility 2.0
Technical Moving Averages 2.5
Technical Oscillators 2.0
Average 2.13

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
TEVA 20 B - - 3.11
ZTS 71 B 1.16% 28.85 15.91
TAK 48 B 1,273.55% 34.98 0.990
HLN 46 B 1.64% 24.36 2.23
RDY 11 B 54.24% 17.69 3.41
BHC 2 B - - -

Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Investment Style Large Value
% Held by Institutions 64.37%

Ownership

Name Date Shares Held
Menora Mivtachim Holdings Ltd. 31 Mar 2025 29,189,316
Migdal Insurance & Financial Holdings Ltd. 31 Mar 2025 26,335,422
Duquesne Family Office Llc 31 Mar 2025 14,879,750
52 Weeks Range
12.47 (-28%) — 22.80 (30%)
Price Target Range
22.00 (25%) — 25.00 (42%)
High 25.00 (Truist Securities, 42.69%) Buy
Median 23.50 (34.13%)
Low 22.00 (B of A Securities, 25.57%) Buy
Average 23.50 (34.13%)
Total 4 Buy
Avg. Price @ Call 17.99
Firm Date Target Price Call Price @ Call
Goldman Sachs 06 Jun 2025 24.00 (36.99%) Buy 17.77
Truist Securities 28 May 2025 25.00 (42.69%) Buy 18.15
JP Morgan 12 May 2025 23.00 (31.28%) Buy 17.96
B of A Securities 08 May 2025 22.00 (25.57%) Buy 18.07
Name Avg. Buy ($) Avg. Sell ($) Net Quantity Net Value ($)
BARER SOL J - - 0 0
CRANE ROSEMARY A - - 0 0
ELSTEIN AMIR - - 0 0
LIEBERMAN GERALD M - - 0 0
MIGNONE ROBERTO - - 0 0
NISEN PERRY - - 0 0
SATCHI-FAINARO RONIT - - 0 0
SHALEV VARDA - - 0 0
VERGIS JANET S. - - 0 0
ZAKS TAL ZVI - - 0 0
Aggregate Net Quantity 0
Aggregate Net Value ($) 0
Aggregate Avg. Buy ($) -
Aggregate Avg. Sell ($) -
Name Holder Date Type Quantity Price Value ($)
MIGNONE ROBERTO Director 06 Jun 2025 Option execute 9,632 - -
BARER SOL J Director 06 Jun 2025 Option execute 17,158 - -
CRANE ROSEMARY A Director 06 Jun 2025 Option execute 9,632 - -
ELSTEIN AMIR Director 06 Jun 2025 Option execute 9,632 - -
LIEBERMAN GERALD M Director 06 Jun 2025 Option execute 9,632 - -
NISEN PERRY Director 06 Jun 2025 Option execute 9,632 - -
SATCHI-FAINARO RONIT Director 06 Jun 2025 Option execute 9,632 - -
SHALEV VARDA Director 06 Jun 2025 Option execute 9,632 - -
ZAKS TAL ZVI Director 06 Jun 2025 Option execute 9,632 - -
VERGIS JANET S. Director 06 Jun 2025 Option execute 9,632 - -
  • 3M
Date Type Details
17 Jun 2025 Announcement Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients
16 Jun 2025 Announcement Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology
16 Jun 2025 Announcement Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology
16 Jun 2025 Announcement Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025
16 Jun 2025 Announcement Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology
03 Jun 2025 Announcement Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement
03 Jun 2025 Announcement Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement
03 Jun 2025 Announcement Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer
03 Jun 2025 Announcement Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer
30 May 2025 Announcement New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025
30 May 2025 Announcement New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025
30 May 2025 Announcement Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS wi...
30 May 2025 Announcement Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS wi...
29 May 2025 Announcement Immuneering to Present at the Jefferies Global Healthcare Conference
29 May 2025 Announcement Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day
29 May 2025 Announcement Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day
27 May 2025 Announcement Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA
27 May 2025 Announcement Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA
27 May 2025 Announcement Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June
27 May 2025 Announcement Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June
22 May 2025 Announcement Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes
22 May 2025 Announcement Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes
20 May 2025 Announcement Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt
20 May 2025 Announcement Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt
20 May 2025 Announcement Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy
20 May 2025 Announcement Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy
19 May 2025 Announcement Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes
19 May 2025 Announcement Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031
19 May 2025 Announcement Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031
19 May 2025 Announcement Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes
15 May 2025 Announcement Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy
15 May 2025 Announcement Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy
12 May 2025 Announcement Teva’s 2024 Healthy Future Report Highlights Sustainability Progress, Including Surpassed Targets Linked to Financial Strategy
12 May 2025 Announcement Teva’s 2024 Healthy Future Report Highlights Sustainability Progress, Including Surpassed Targets Linked to Financial Strategy
07 May 2025 Announcement Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook Improved
07 May 2025 Announcement Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook Improved
07 May 2025 Announcement Teva to Host Innovation & Strategy Day on Thursday, May 29 in New York City
07 May 2025 Announcement Teva to Host Innovation & Strategy Day on Thursday, May 29 in New York City
05 May 2025 Announcement Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)
05 May 2025 Announcement Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)
05 May 2025 Announcement Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates
07 Apr 2025 Announcement Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention
07 Apr 2025 Announcement Teva and Samsung Bioepis Announce Biosimilar EPYSQLI® (eculizumab-aagh) Injection Now Available in the United States
07 Apr 2025 Announcement Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention
02 Apr 2025 Announcement Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference
31 Mar 2025 Announcement New Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable
31 Mar 2025 Announcement New Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable
27 Mar 2025 Announcement Teva Releases Q1 2025 Aide Memoire
27 Mar 2025 Announcement Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025
27 Mar 2025 Announcement Teva Releases Q1 2025 Aide Memoire
27 Mar 2025 Announcement Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025
21 Mar 2025 Announcement Immuneering Corporation Announces Grant of Inducement Award
20 Mar 2025 Announcement Immuneering Names Dr. Igor Matushansky as Chief Medical Officer
20 Mar 2025 Announcement Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
Show more
5Y Average Dividend Yield 0.00%
Ex Date Announcement Date Payment Date Details
27 Nov 2017 06 Nov 2017 12 Dec 2017 0.085 Cash
25 Aug 2017 - 14 Sep 2017 0.07225 Cash
01 Jun 2017 - 22 Jun 2017 0.289 Cash
28 Feb 2017 - 20 Mar 2017 0.289 Cash
01 Dec 2016 - 20 Dec 2016 0.289 Cash
18 Aug 2016 - 08 Sep 2016 0.289 Cash
20 May 2016 - 07 Jun 2016 0.289 Cash
25 Feb 2016 - 14 Mar 2016 0.289 Cash
13 Nov 2015 - 03 Dec 2015 0.289 Cash
18 Aug 2015 - 03 Sep 2015 0.289 Cash
15 May 2015 - 04 Jun 2015 0.289 Cash
17 Feb 2015 - 03 Mar 2015 0.293636 Cash
13 Nov 2014 - 02 Dec 2014 0.269593 Cash
19 Aug 2014 - 04 Sep 2014 0.291112 Cash
16 May 2014 - 02 Jun 2014 0.29777 Cash
20 Feb 2014 - 10 Mar 2014 0.293019 Cash
18 Nov 2013 - 03 Dec 2013 0.277541 Cash
16 Aug 2013 - 03 Sep 2013 0.273656 Cash
16 May 2013 - 03 Jun 2013 0.268249 Cash
19 Feb 2013 - 07 Mar 2013 0.266857 Cash
13 Nov 2012 - 03 Dec 2012 0.202399 Cash
13 Aug 2012 - 04 Sep 2012 0.208281 Cash
17 May 2012 - 04 Jun 2012 0.196042 Cash
23 Feb 2012 - 13 Mar 2012 0.197212 Cash
10 Nov 2011 - 07 Dec 2011 0.17539 Cash
09 Nov 2011 - 07 Dec 2011 0.171904 Cash
04 Aug 2011 - 25 Aug 2011 0.196304 Cash
03 Aug 2011 - 25 Aug 2011 0.199624 Cash
19 May 2011 - 07 Jun 2011 0.199925 Cash
10 Feb 2011 - 07 Mar 2011 0.216813 Cash
08 Nov 2010 - 06 Dec 2010 0.173008 Cash
02 Aug 2010 - 26 Aug 2010 0.166994 Cash
10 May 2010 - 04 Jun 2010 0.163153 Cash
19 Feb 2010 - 17 Mar 2010 0.164033 Cash
06 Nov 2009 - 04 Dec 2009 0.125431 Cash
03 Aug 2009 - 27 Aug 2009 0.124804 Cash
08 May 2009 - 03 Jun 2009 0.120261 Cash
23 Feb 2009 - 19 Mar 2009 0.111992 Cash
07 Nov 2008 - 05 Dec 2008 0.09309 Cash
01 Aug 2008 - 27 Aug 2008 0.10421 Cash
13 May 2008 - 05 Jun 2008 0.11255 Cash
12 May 2008 - 05 Jun 2008 0.10919 Cash
18 Feb 2008 - 13 Mar 2008 0.10429 Cash
15 Feb 2008 - 13 Mar 2008 0.10174 Cash
02 Nov 2007 - 28 Nov 2007 0.084 Cash
10 Aug 2007 - 06 Sep 2007 0.08015 Cash
10 May 2007 - 05 Jun 2007 0.0833 Cash
16 Feb 2007 - 15 Mar 2007 0.07866 Cash
10 Nov 2006 - 06 Dec 2006 0.06569 Cash
11 Aug 2006 - 08 Sep 2006 0.06434 Cash
12 May 2006 - 07 Jun 2006 0.06257 Cash
06 Mar 2006 - 30 Mar 2006 0.06072 Cash
10 Nov 2005 - 07 Dec 2005 0.05188 Cash
11 Aug 2005 - 07 Sep 2005 0.05431 Cash
05 May 2005 - 01 Jun 2005 0.0559 Cash
17 Feb 2005 - 17 Mar 2005 0.0559 Cash
09 Nov 2004 - 06 Dec 2004 0.0414 Cash
09 Aug 2004 - 07 Sep 2004 0.0401 Cash
10 May 2004 - 07 Jun 2004 0.0768 Cash
20 Feb 2004 - 22 Mar 2004 0.0781 Cash
13 Nov 2003 - 12 Dec 2003 0.0587 Cash
08 Aug 2003 - 08 Sep 2003 0.0596 Cash
08 May 2003 - 06 Jun 2003 0.0581 Cash
24 Feb 2003 - 24 Mar 2003 0.0546 Cash
07 Nov 2002 - 06 Dec 2002 0.0738 Cash
19 Aug 2002 - 16 Sep 2002 0.0738 Cash
20 May 2002 - 17 Jun 2002 0.0701 Cash
15 Feb 2002 - 18 Mar 2002 0.0772 Cash
16 Nov 2001 - 17 Dec 2001 0.0531 Cash
20 Aug 2001 - 17 Sep 2001 0.0498 Cash
17 May 2001 - 15 Jun 2001 0.0486 Cash
08 Mar 2001 - 06 Apr 2001 0.0477 Cash
16 Nov 2000 - 15 Dec 2000 0.0407 Cash
24 Aug 2000 - 21 Sep 2000 0.0415 Cash
19 May 2000 - 19 Jun 2000 0.0405 Cash
17 Feb 2000 - 27 Mar 2000 0.0838 Cash
04 Nov 1999 - 30 Nov 1999 0.0529 Cash
18 Aug 1999 - 13 Sep 1999 0.0527 Cash
21 May 1999 - 15 Jun 1999 0.054 Cash
08 Mar 1999 - 30 Mar 1999 0.055 Cash
20 Nov 1998 - 11 Dec 1998 0.053 Cash
21 Aug 1998 - 11 Sep 1998 0.058 Cash
21 May 1998 - 22 Jun 1998 0.0639 Cash
12 Mar 1998 - 31 Mar 1998 0.0649 Cash
20 Nov 1997 - 09 Dec 1997 0.0666 Cash
25 Aug 1997 - 11 Sep 1997 0.0667 Cash
23 May 1997 - 12 Jun 1997 0.069 Cash
07 Mar 1997 - 26 Mar 1997 0.0695 Cash
20 Nov 1996 - 09 Dec 1996 0.0468 Cash
26 Aug 1996 - 12 Sep 1996 0.0492 Cash
23 May 1996 - 12 Jun 1996 0.0477 Cash
07 Mar 1996 - 26 Mar 1996 0.0504 Cash
20 Nov 1995 - 07 Dec 1995 0.0485 Cash
14 Aug 1995 - 30 Aug 1995 0.0488 Cash
17 May 1995 - 07 Jun 1995 0.051 Cash
07 Mar 1995 - 04 Apr 1995 0.0512 Cash
Show more

Annual Dividend Yield

Year Annual Dividend ($) Frequency/Year Yield %
2017 0.735 4 3.88
2016 1.16 4 3.19
2015 1.16 4 1.77
2014 1.15 4 2.00
2013 1.09 4 2.71
2012 0.804 4 2.15
2011 1.16 6 2.87
2010 0.667 4 1.28
2009 0.482 4 0.86
2008 0.625 6 1.47
2007 0.326 4 0.70
2006 0.253 4 0.82
2005 0.218 4 0.51
2004 0.236 4 0.79
2003 0.231 4 0.82
2002 0.295 4 1.53
2001 0.199 4 1.29
2000 0.207 4 1.13
1999 0.215 4 2.40
1998 0.240 4 4.72
1997 0.272 4 4.60
1996 0.194 4 3.09
1995 0.200 4 3.44
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria